About MCVI | Foundation | Physicians | Locations | Specialty Services | Testing | Electrophysiology Research | Events | Job Opportunities | Patient Links | Referring Physicians | Articles

SPIRIT IV

Principal Investigator:
Daniel Lee, MD        (Bay Med)

Sub-Investigators:
Stephen Mattichak, MD

Sponsor:
Medtronic, Abbott Vascular

Study Purpose:
A Clinical Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects with de novo Native Coronary Artery Lesions.

Objective:
To see if a new drug-coated stent system is safe and effective in treating the narrowing of your heart artery.  The new drug-coated stent is the XIENCE^™ V Everolimus Eluting Coronary Stent System (the “XIENCE V Stent”).  The XIENCE V Stent will be compared to a drug-coated stent that has been approved by the U.S. Food and Drug Administration (“FDA”) for treating narrowed arteries.  The approved stent is the TAXUS^Ò EXPRESS^2™ Paclitaxel-Eluting Coronary Stent (the “TAXUS Stent”).  If the next generation TAXUS stent is approved by FDA during the Study, the newer TAXUS stent will be used for comparison.

Status:
Active enrollment
 

If you have any questions, please feel free to contact the coordinators, and they will be happy to answer any questions you have regarding this study.